Sanara Medtech Inc
SMTI
View Detailed Chart
20.240USD
+0.200+1.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
180.76MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.00%
5 Days
-8.00%
1 Month
-18.65%
6 Months
-17.56%
Year to Date
-13.32%
1 Year
-42.82%
View Detailed Chart
TradingKey Stock Score of Sanara Medtech Inc
Currency: USD Updated: 2026-02-06Key Insights
Sanara Medtech Inc's fundamentals are relatively stable, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 84 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 40.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sanara Medtech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Sanara Medtech Inc Highlights
StrengthsRisks
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 89.06% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 86.67M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 86.67M.
Overvalued
The company’s latest PE is -4.65, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.18M shares, decreasing 1.80% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 183.14K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
40.000
Target Price
+99.60%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sanara Medtech Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Sanara Medtech Inc Info
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
Ticker SymbolSMTI
CompanySanara Medtech Inc
CEOMuppalla (Suresh V)
Websitehttps://sanaramedtech.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
67843.990
-2126.140 (-3.04%)
282.580
+22.390 (+8.61%)
2007.410
-44.320 (-2.16%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
